Phase 3 Readout~month

Phase 3 Topline: Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung C

Name: Phase 3 Topline: Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung C
Start: 2028-08-31

August 31, 2028

Company: Onconetix, Inc. (ONCO)
Drug: onc-392
Indication: Non Small Cell Lung Cancer

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung C — ONCO Phase 3 Readout | BioSniper